Yazar "Ozguroglu, M." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Gumus, M.; Kilickap, S.; Sezer, A.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.[Abstract Not Available]Öğe EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year update(Elsevier Science Inc, 2023) Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Garassino, M. C.; Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]
